Beta3-adrenergic agonists: potential therapeutics for obesity

Area of Science:

• Pharmacology
• Metabolism
• Obesity Research

Background:

• Previous beta3-adrenergic receptor agonists failed in clinical trials due to weak activity against human receptors.
• Early drug candidates did not yield sustained increases in metabolic rate or significant weight loss in human studies.

Purpose of the Study:

• To explain the poor performance of earlier beta3-adrenergic receptor agonists in human clinical trials.
• To introduce a new generation of beta3-adrenergic receptor agonists optimized for the human receptor.
• To evaluate the potential of these novel agents in addressing obesity and related metabolic parameters.

Main Methods:

• Cloning of beta3-adrenoceptors across species.
• Pharmacological evaluations of early investigational drugs.
• Integration of findings into the discovery of new, human-optimized agents.

Main Results:

• Early agonists demonstrated weak activity against the human beta3-adrenergic receptor.
• New generation compounds show optimized activity for the human receptor.
• These novel agents are progressing through late preclinical and early clinical development.

Conclusions:

• The poor efficacy of earlier drugs was attributed to their low activity against human beta3-adrenergic receptors.
• New, human-optimized beta3-adrenergic agonists are anticipated to effectively target the obese state.
• Further research will elucidate the role of beta3-adrenergic agonists in improving human metabolic parameters.